Here's a review you can publish:
> My analysis on Twist Bioscience (TWST)
The fact that TD Cowen considers Twist Bioscience as its top investment pick among small and mid-caps is a strong signal. The company operates in a strategic sector: DNA synthesis and life sciences tools, a market benefiting from both biotech growth and the rise of artificial intelligence in biological research. Twist Bioscience
Positive points:
The company shows solid revenue growth and a gradual improvement in its margins.
TD Cowen believes the market still undervalues its profitability potential and has raised its price target to $89.
The increasing integration of AI in drug discovery and biological engineering could support demand for Twist's services for several years.
Caution points:
The stock has already surged significantly in 2026, with an increase of over 100% since the start of the year, raising the risk of short-term corrections.
The company is not yet a profitability model comparable to the major players in the sector and remains exposed to biotech investment cycles.
Some investors are cautious due to past controversies and debates around the company's operational quality.
I view Twist Bioscience as an interesting growth stock for investors willing to accept high volatility. The potential is real thanks to the convergence of biotechnology and artificial intelligence, but after such a spike in the stock price, a consolidation phase wouldn't be surprising. In the long term, the stock remains attractive, but it’s important to manage risk and avoid getting swept up in market euphoria. 📈🧬WTIFallsBelow$80#USADPEmploymentChangeSlipsTo25500 OilFallsBelow$80$NVDAB $SPCXB $TSLAB
> My analysis on Twist Bioscience (TWST)
The fact that TD Cowen considers Twist Bioscience as its top investment pick among small and mid-caps is a strong signal. The company operates in a strategic sector: DNA synthesis and life sciences tools, a market benefiting from both biotech growth and the rise of artificial intelligence in biological research. Twist Bioscience
Positive points:
The company shows solid revenue growth and a gradual improvement in its margins.
TD Cowen believes the market still undervalues its profitability potential and has raised its price target to $89.
The increasing integration of AI in drug discovery and biological engineering could support demand for Twist's services for several years.
Caution points:
The stock has already surged significantly in 2026, with an increase of over 100% since the start of the year, raising the risk of short-term corrections.
The company is not yet a profitability model comparable to the major players in the sector and remains exposed to biotech investment cycles.
Some investors are cautious due to past controversies and debates around the company's operational quality.
I view Twist Bioscience as an interesting growth stock for investors willing to accept high volatility. The potential is real thanks to the convergence of biotechnology and artificial intelligence, but after such a spike in the stock price, a consolidation phase wouldn't be surprising. In the long term, the stock remains attractive, but it’s important to manage risk and avoid getting swept up in market euphoria. 📈🧬WTIFallsBelow$80#USADPEmploymentChangeSlipsTo25500 OilFallsBelow$80$NVDAB $SPCXB $TSLAB